How is Google's GPay operating without authorisation: Delhi HC asks RBI

4.jpg

The Delhi High Court on Wednesday asked the Reserve Bank of India (RBI) how Google's mobile payment app, GPay, was facilitating financial transactions without the requisite authorisation from it.
A bench of Chief Justice Rajendra Menon and Justice A J Bhambhani posed the query to RBI while hearing a PIL which claimed that GPay was acting as a payments system provider in violation of the Payments and Settlements Act as it has no valid authorisation from the central bank of the country to carry out such functions.

The court issued notice to RBI and Google India seeking their stand on the issue raised in the plea by Abhijit Mishra, who has contended that GPay does not figure in RBI's list of authorised 'payment systems operators' released by the central bank on March 20, 2019.

Comments

Post a Comment

Popular posts from this blog

I'm Tamilian first, says Sathyaraj post 'Baahubali 2' row

Image
After pro-Kannada organisations threatened to stall ' Baahubali  2' in Karnataka, veteran Tamil actor Sathyaraj has apologised over his remarks on the Cauvery water dispute while categorically stating that he would continue to support these issues as he is a Tamilian first and then an actor. While expressing his views via a WhatsApp video, the actor, who expressed his anuish over the Cauvery water issue nine years back, said that he does not want anyone from his upcoming movie 'Baahubali 2' to bear the losses. He noted,"Nevertheless, in the coming days be it Tamil people, Cauvery issue, farmers issue or any other issue, I would continue to voice my support against these issues." "And if anyone thinks that my statement caused any harm to the producers and directors, then I would request them not to cast this small, meager actor in their films. I don't want anyone to suffer any kind of loss because I would prefer to live and die as a Tamilian ...
Read more

Flipkart Mobile Bonanza sale: Poco F1 for Rs 18,999 & other deals on phones

Image
Business Standard : Flipkart, a home-grown e-commerce marketplace, is currently hosting a four-day sale in which the online shopping portal is offering discounts, cashback, exchange offers and no cost equated monthly instalments on mobile phones. Named Flipkart Mobile Bonanza , the sale started on November 19 and will continue until November 22. Launched earlier this year, the LG G7 ThinQ (review) is a flagship smartphone with top-notch specifications and features. In its price segment, it is the only phone that comes with IP68 water and dust resistance protection, artificial intelligence-based imaging and wireless charging support. In the sale, the phone is available at a discounted price of Rs 29,999. Flipkart is also offering up to Rs 17,900 off on exchange and an additional Rs 3,000 off over regular exchange value. The phone is also eligible for no cost EMI. Coming from the stable of Xiaomi, the Poco F1 (review) is one of the cheapest smartphones with the flagship proce...
Read more

Ipca and Cadila Healthcare gear up to make drug for coronavirus

Image
Hydroxychloroquine, a drug whose largest manufacturer is an Indian firm, has shot into the limelight after the US president advocated it as potential therapy for COVID-19 . Ipca is the biggest producer of the drug. Cadila Healthcare, based in Ahmedabad, too is a major player. Both are gearing up to meet the demand and have said there will be enough supplies. On top of this, a combination hydroxychloroquine and azithro­mycin, a common antibiotic, is being considered. Vadodara-based drug major Alembic is the domestic market leader with its brand Azithral, with an almost 30 per cent share. Sources said the country’s apex health research body, the Indian Council of Medical Research (ICMR), had included the drug in its protocol for treating COVID-19. The ICMR, however, has not confirmed this. Pankaj Patel, chairman of Cadila Healthcare, said the firm was producing 20 tonnes of Hydroxy­chloroquine per month, and had started ramping up production. Read Complete Article ...
Read more